135 related articles for article (PubMed ID: 34648283)
1. Human Estrogen Receptor α Antagonists. Part 1: 3-D QSAR-Driven Rational Design of Innovative Coumarin-Related Antiestrogens as Breast Cancer Suppressants through Structure-Based and Ligand-Based Studies.
Mihović N; Tomašević N; Matić S; Mitrović MM; Kostić DA; Sabatino M; Antonini L; Ragno R; Mladenović M
J Chem Inf Model; 2021 Oct; 61(10):5028-5053. PubMed ID: 34648283
[TBL] [Abstract][Full Text] [Related]
2. Human estrogen receptor α antagonists, part 2: Synthesis driven by rational design, in vitro antiproliferative, and in vivo anticancer evaluation of innovative coumarin-related antiestrogens as breast cancer suppressants.
Kurtanović N; Tomašević N; Matić S; Mitrović MM; Kostić DA; Sabatino M; Antonini L; Ragno R; Mladenović M
Eur J Med Chem; 2022 Jan; 227():113869. PubMed ID: 34710747
[TBL] [Abstract][Full Text] [Related]
3. Human Estrogen Receptor Alpha Antagonists, Part 3: 3-D Pharmacophore and 3-D QSAR Guided Brefeldin A Hit-to-Lead Optimization toward New Breast Cancer Suppressants.
Kurtanović N; Tomašević N; Matić S; Proia E; Sabatino M; Antonini L; Mladenović M; Ragno R
Molecules; 2022 Apr; 27(9):. PubMed ID: 35566172
[TBL] [Abstract][Full Text] [Related]
4. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
Elife; 2022 May; 11():. PubMed ID: 35575456
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of selective estrogen receptor modulator activity in human breast cancer cells: identification of novel nuclear cofactors of antiestrogen-ERα complexes by interaction proteomics.
Cirillo F; Nassa G; Tarallo R; Stellato C; De Filippo MR; Ambrosino C; Baumann M; Nyman TA; Weisz A
J Proteome Res; 2013 Jan; 12(1):421-31. PubMed ID: 23170835
[TBL] [Abstract][Full Text] [Related]
7. Ligands specify estrogen receptor alpha nuclear localization and degradation.
Kocanova S; Mazaheri M; Caze-Subra S; Bystricky K
BMC Cell Biol; 2010 Dec; 11():98. PubMed ID: 21143970
[TBL] [Abstract][Full Text] [Related]
8. Differential activation of wild-type estrogen receptor alpha and C-terminal deletion mutants by estrogens, antiestrogens and xenoestrogens in breast cancer cells.
Wu F; Safe S
J Steroid Biochem Mol Biol; 2007 Jan; 103(1):1-9. PubMed ID: 17141713
[TBL] [Abstract][Full Text] [Related]
9. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
[TBL] [Abstract][Full Text] [Related]
10. Elucidating Binding Sites and Affinities of ERα Agonists and Antagonists to Human Alpha-Fetoprotein by In Silico Modeling and Point Mutagenesis.
Moldogazieva NT; Ostroverkhova DS; Kuzmich NN; Kadochnikov VV; Terentiev AA; Porozov YB
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019136
[TBL] [Abstract][Full Text] [Related]
11. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.
Luo G; Li X; Zhang G; Wu C; Tang Z; Liu L; You Q; Xiang H
Eur J Med Chem; 2017 Nov; 140():252-273. PubMed ID: 28942113
[TBL] [Abstract][Full Text] [Related]
12. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
Kim K; Thu N; Saville B; Safe S
Mol Endocrinol; 2003 May; 17(5):804-17. PubMed ID: 12576490
[TBL] [Abstract][Full Text] [Related]
13. Coumarin-Fatty Acid Conjugates as Potential ERα/AKT-1 Antagonists for ER Positive Breast Cancer.
Selvaraj J; John JBA; Joghee NM; Antony J; Wadhwani A; Natarajan J
Anticancer Agents Med Chem; 2020; 20(4):437-449. PubMed ID: 31746305
[TBL] [Abstract][Full Text] [Related]
14. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists.
Barkhem T; Carlsson B; Nilsson Y; Enmark E; Gustafsson J; Nilsson S
Mol Pharmacol; 1998 Jul; 54(1):105-12. PubMed ID: 9658195
[TBL] [Abstract][Full Text] [Related]
15. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER.
Zekas E; Prossnitz ER
BMC Cancer; 2015 Oct; 15():702. PubMed ID: 26470790
[TBL] [Abstract][Full Text] [Related]
17. Decreased responsiveness of naturally occurring mutants of human estrogen receptor alpha to estrogens and antiestrogens.
Komagata S; Nakajima M; Tsuchiya Y; Katoh M; Kizu R; Kyo S; Yokoi T
J Steroid Biochem Mol Biol; 2006 Jul; 100(1-3):79-86. PubMed ID: 16713253
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biochemical characterization of a series of 17α-perfluoroalkylated estradiols as selective ligands for estrogen receptor α.
Eignerová B; Sedlák D; Dracínský M; Bartunek P; Kotora M
J Med Chem; 2010 Oct; 53(19):6947-53. PubMed ID: 20812681
[TBL] [Abstract][Full Text] [Related]
19. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
20. Estrogen Receptor α (ERα)-targeting Compounds and Derivatives: Recent Advances in Structural Modification and Bioactivity.
Guo WY; Zeng SM; Deora GS; Li QS; Ruan BF
Curr Top Med Chem; 2019; 19(15):1318-1337. PubMed ID: 31215379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
